A comprehensive pharma AI visibility audit tests real buyer journey questions across ChatGPT, Gemini, Perplexity, Claude and Grok, benchmarks competitor visibility, and inspects website structure and citation quality. Most general AI visibility tools do none of these three things in a way useful to a pharma supplier. This article explains the evaluation criteria so you can judge any platform, including ours, against the same standard.

Disclosure: this article is published by AEO Dose, which provides AI visibility and AEO readiness audits for pharma businesses. The audit methodology referenced here is our own. The criteria below are written to help any pharma business evaluate any platform or service, including ours, against the same standard.
In this article

What pharma buyers actually ask AI assistants (and why that matters for audits)

Pharma buyers typically do not type a company name into an AI assistant. A sourcing manager at a formulation company asks Perplexity to "list GMP-certified CDMOs for oral solid dose with a track record in controlled substances," or asks ChatGPT "which excipient suppliers provide co-processed directly compressible blends with regulatory support documentation." These are capability and qualification questions, not brand lookups. The buyer is building a shortlist before anyone has heard of you.

That behavior sets the standard for what an audit has to measure. If a tool only checks whether your brand name is mentioned when prompted, it answers a question your buyers are not asking. AI visibility, in the sense that matters commercially, is whether an assistant surfaces you when a buyer describes a need in their own words. For a fuller grounding in what AI visibility means before you evaluate audit tools, the Understanding AI Visibility and AEO cluster covers the definitions this article builds on.

What makes an AI visibility audit comprehensive

An audit is comprehensive when it tests how you appear across the assistants your buyers use, measures you against the competitors you actually lose deals to, and examines the website signals that determine whether an assistant can cite you at all. A visibility score on its own is a thermometer reading. It tells you the temperature without telling you why the room is cold.

The three dimensions work together. Platform coverage tells you where you are visible. Buyer journey question testing tells you for which needs you surface. Website and citation inspection tells you why. Drop any one and you lose the ability to act on the result. A score of 40 means nothing until you know it comes from thin capability pages, or missing structured data, or a competitor whose content answers the buyer's question more directly than yours.

Why general AI visibility tools miss the mark for pharma

Most general AI visibility tools were built for consumer brands, and that design choice shows the moment you point them at a pharma supplier. They track brand mentions, sentiment, and share of voice across broad consumer queries. None of that maps to how an API manufacturer or a CDMO gets shortlisted.

Here is the pushback worth sitting with: the assumption that a general tool is "good enough" because it checks AI assistants quietly fails on the question set. A consumer tool does not know to ask about DMF filings, co-processed excipients, controlled substance licensing, or stability study support, because nobody built it to. It cannot interpret a weak result either. When your visibility is low for "nutraceutical contract manufacturer with third-party certification," a generic tool reports the number. It does not tell you the result stems from a website that lists certifications as logos in a footer rather than as crawlable, structured text an assistant can parse. Constructing the right questions and reading the results both require pharma grounding the generic tool does not have.

The five platforms a comprehensive audit should cover

A comprehensive audit covers ChatGPT, Gemini, Perplexity, Claude and Grok, because these are the current five-platform standard set and each behaves differently. ChatGPT and Claude lean on trained knowledge and reasoning. Perplexity and Gemini pull live sources and cite them inline. Grok draws on real-time signals. The same buyer question produces different answers, and different citations, depending on which assistant the buyer opens.

This is why single-platform checks mislead. You can be surfaced reliably in one assistant and absent from another for the identical query. A tool that reports a single aggregate "AI visibility" figure hides that split. AEO Dose's Free Check covers 2 platforms and 10 real buyer questions as a starting read, and the Full Audit extends across all five. Whatever platform you evaluate, confirm it names the specific assistants it tests rather than referring to "major AI assistants" as a black box.

Testing real buyer journey questions, not brand queries

The questions an audit tests matter as much as the platforms it runs them on, and they should follow the buyer journey rather than your brand name. A useful audit builds its question set across five themes: discovery (how buyers find suppliers in your category), evaluation (how they compare and shortlist), product and capability (whether your specific services surface for specific needs), commercial (pricing models, minimum order quantities, lead times), and support (regulatory documentation, technical help, stability data).

Brand queries flatter you. Asking an assistant to describe your company tends to return something, because the model has your name as the anchor. That result is close to worthless for sourcing, where buyers start from need. Testing across the five journey themes shows where you surface when the buyer has never heard of you, which is the visibility that generates net-new inquiries. A comprehensive audit also runs on a repeatable cycle rather than a one-off snapshot, because assistant answers shift as models update. The Audit and Optimization Process cluster explains the Audit, Optimize, Build Authority, Measure, Repeat cycle that keeps the read current.

How audits differ by business type: CDMO, excipient, nutraceutical, oral care

An audit for a CDMO is not the same audit as one for a nutraceutical or oral care brand, because the buyer, the question set, and the citation sources all change. A CDMO audit tests manufacturing-capability questions: dosage forms, batch scales, certifications, and regulatory track record. The buyer is a technical sourcing team, and the questions are dense with qualification criteria.

An excipient supplier audit centres on material specifications, functional grades, and compliance documentation, because formulators ask about performance properties and regulatory support. A nutraceutical brand audit shifts toward ingredient claims, certifications, and consumer-adjacent discovery, where an assistant may cite the brand without linking to it. An oral care product manufacturer sits closer still to consumer queries, blending ingredient and efficacy questions with retail discovery. Each business type needs its own question set and its own sense of what a good citation looks like. The Industry-Specific Visibility Challenges cluster goes deeper on each of these business types and the distinct signals each one needs to get right.

What a useful audit report delivers beyond a score

A useful report tells you what to fix, in what order, and why, rather than handing you a number and walking away. The score is the headline. The body is the diagnosis: which buyer questions you lost, to which competitors, on which platforms, and what on your website caused the gap.

Concretely, a report earns its keep when it names the specific pages and signals holding you back. Thin capability content that does not answer the buyer's question directly. Certifications presented as images rather than structured, crawlable text. Missing or inconsistent schema that leaves an assistant unsure what your company does. A competitor whose content answers "GMP CDMO for sterile injectables" more completely than yours. That level of detail, benchmarked against the competitors you lose deals to, is the difference between a report you can act on this quarter and a dashboard you glance at and forget.

Questions to ask when evaluating any AI visibility audit platform

Ask any platform these questions before you commit, and judge every option, including ours, by the same answers. First: which specific assistants do you test, named individually? Second: do you build questions from my buyers' real sourcing journey, or do you test my brand name? Third: do you benchmark me against my actual competitors? Fourth: does your report inspect my website structure and citation signals, or only report a score? Fifth: do you understand my business type well enough to construct the right questions and interpret the results?

Pharma grounding sits under the last question in particular. Constructing a CDMO question set and reading why an excipient supplier is invisible both take industry knowledge. Our own methodology is built on 12-plus years of pharma ERP implementation and Computer System Validation work alongside B.Pharma industry grounding, which is what lets an audit ask the right questions and interpret the answers. Hold whichever platform you choose to that bar.

The practical next step is to apply these five questions to a real audit rather than a sales deck. Run a check, read what it names, and see whether it meets the standard above.

Get Started

Apply these criteria to your own brand. See which platforms mention you, which buyer questions you surface for, and what your website signals tell AI assistants about your capabilities.

Get Your Free AI Visibility Check

Frequently asked questions

What makes an AI visibility audit comprehensive versus superficial?
A comprehensive audit tests all five major assistants, builds questions from your buyers' real sourcing journey, benchmarks you against actual competitors, and inspects the website signals that determine whether an assistant can cite you. A superficial audit reports a single visibility score from brand-name queries on one or two platforms. The difference is actionability: a comprehensive report tells you which questions you lost, to whom, on which platform, and what on your site to fix. A score alone tells you the temperature without the diagnosis.
Why do most general AI visibility tools fail when applied to pharma businesses?
Most general tools were built for consumer brands, so they track brand mentions and sentiment across broad queries. They were not built to ask about DMF filings, co-processed excipients, controlled substance licensing, or stability support, which is how pharma buyers actually shortlist suppliers. They also cannot interpret a weak result in pharma terms. When your visibility is low for a capability query, a generic tool reports the number but cannot trace it to thin capability pages or certifications buried as footer logos rather than crawlable text.
What platforms should a pharma AI visibility audit cover?
A comprehensive audit covers ChatGPT, Gemini, Perplexity, Claude and Grok as the current five-platform standard set. Each behaves differently. ChatGPT and Claude lean on trained knowledge and reasoning, Perplexity and Gemini pull and cite live sources inline, and Grok draws on real-time signals. The same buyer question can surface you reliably in one assistant and leave you absent from another. A single aggregate figure hides that split, so confirm any platform names the specific assistants it tests before you rely on its results.
What types of buyer questions should a pharma audit test?
Test questions across five buyer journey themes: discovery (how buyers find suppliers in your category), evaluation (how they compare and shortlist), product and capability (whether your specific services surface for specific needs), commercial (pricing, minimum order quantities, lead times), and support (regulatory documentation and technical help). Avoid relying on brand-name queries, which flatter you because the model already has your name as an anchor. Journey questions reveal whether you surface when a buyer who has never heard of you describes a need in their own words.
How does an audit for a CDMO differ from one for a nutraceutical brand?
A CDMO audit tests manufacturing-capability questions: dosage forms, batch scales, certifications, and regulatory track record, aimed at a technical sourcing team. A nutraceutical brand audit shifts toward ingredient claims, certifications, and consumer-adjacent discovery, where an assistant may cite the brand without linking to it. The buyer, the question set, and the citation sources all change. Each business type needs its own question set and its own sense of what a good, useful citation actually looks like for that buyer.
What should an audit report actually tell you beyond a visibility score?
It should tell you what to fix, in what order, and why. Beyond the headline score, a useful report names which buyer questions you lost, to which competitors, on which platforms, and what on your website caused each gap: thin capability content, certifications presented as images instead of crawlable text, missing or inconsistent schema, or a competitor whose content answers a query more completely. That level of detail, benchmarked against competitors you lose deals to, is the difference between a report you can act on and a dashboard you forget.
What questions should I ask when evaluating any AI visibility audit platform?
Ask five things. Which specific assistants do you test, named individually? Do you build questions from my buyers' sourcing journey or from my brand name? Do you benchmark me against my actual competitors? Does your report inspect my website structure and citation signals or only report a score? And do you understand my business type well enough to construct the right questions and interpret the results? Judge every option, including ours, by the same answers before committing.